Pub Date : 2024-03-04DOI: 10.29235/1814-6023-2024-21-1-79-88
N. Karlovich, O. N. Shishko, M. A. Malyshko, E. V. Yurenya, T. V. Mokhort
Hyperprolactinemia (HP) is a persistent pathological increase in a prolactin serum concentration amounting to more than 20 ng/ml in males and 25 ng/ml in females and leads to developing the pathological symptom complex of HP primarily from the reproductive system. To confirm the persistent etiology of HP and to eliminate physiological short-term hormone enhancement, a number of recommendations, including Russian and Belarusian, were proposed to make several prolactin measurements.This study included 120 patients with HP (96 females, 78.0 %) and (27 males, 22.0 %) aged 18–50 years who sought medical help at the Health Institution “Minsk City Clinical Endocrinology Center” in the period from December 2022 to September 2023. After catheterizing the vein, a venous cannula was inserted and blood was taken immediately after cannulating (T0), and then in 60 minutes (T1) and 120 minutes (T2). The cannulated prolactin test results were considered positive – with HP remaining in all three samples (T0, T1, T2), questionable – if HP was kept at T0 and T1, and negative if HP was only at T0. When evaluating the cannulated test results, true HP is 36.7 %. Patients with a positive cannulated test had a higher prolactin at T0, which was 888.5 mME/L (U = 97.0; z = 7.92; p < 0.001). Patients with stress-induced HP (negative test) and patients with true HP (positive test) had no statistically significant differences in age and occurrence frequency of specific and non-specific complaints and symptoms for HP.
高泌乳素血症（HP）是指泌乳素血清浓度持续病理性升高，男性超过20纳克/毫升，女性超过25纳克/毫升，导致主要来自生殖系统的HP病理症状综合征。为了确认人类乳头瘤病毒的顽固病因并消除生理上的短期激素增强，包括俄罗斯和白俄罗斯在内的许多国家都提出了进行多次催乳素测量的建议。本研究纳入了2022年12月至2023年9月期间在 "明斯克市临床内分泌中心 "医疗机构就诊的120名18-50岁人类乳头瘤病毒患者（其中女性96人，占78.0%）和（男性27人，占22.0%）。静脉导管插入后，立即抽血（T0），然后在 60 分钟（T1）和 120 分钟（T2）后抽血。插管催乳素检测结果被认为是阳性的--在所有三个样本（T0、T1、T2）中都残留有催乳素；如果在 T0 和 T1 中都残留有催乳素，则检测结果有问题；如果只在 T0 中残留有催乳素，则检测结果为阴性。在评估插管检测结果时，真正的 HP 为 36.7%。插管检测呈阳性的患者在T0时泌乳素较高，为888.5 mME/L（U = 97.0; z = 7.92; p < 0.001）。应激诱发的高血压患者（阴性）和真正的高血压患者（阳性）在年龄、高血压的特异性和非特异性主诉和症状的发生频率方面没有明显的统计学差异。
{"title":"Cannulated prolactin test in the diagnosis of the hyperprolactinemia syndrome","authors":"N. Karlovich, O. N. Shishko, M. A. Malyshko, E. V. Yurenya, T. V. Mokhort","doi":"10.29235/1814-6023-2024-21-1-79-88","DOIUrl":"https://doi.org/10.29235/1814-6023-2024-21-1-79-88","url":null,"abstract":"Hyperprolactinemia (HP) is a persistent pathological increase in a prolactin serum concentration amounting to more than 20 ng/ml in males and 25 ng/ml in females and leads to developing the pathological symptom complex of HP primarily from the reproductive system. To confirm the persistent etiology of HP and to eliminate physiological short-term hormone enhancement, a number of recommendations, including Russian and Belarusian, were proposed to make several prolactin measurements.This study included 120 patients with HP (96 females, 78.0 %) and (27 males, 22.0 %) aged 18–50 years who sought medical help at the Health Institution “Minsk City Clinical Endocrinology Center” in the period from December 2022 to September 2023. After catheterizing the vein, a venous cannula was inserted and blood was taken immediately after cannulating (T0), and then in 60 minutes (T1) and 120 minutes (T2). The cannulated prolactin test results were considered positive – with HP remaining in all three samples (T0, T1, T2), questionable – if HP was kept at T0 and T1, and negative if HP was only at T0. When evaluating the cannulated test results, true HP is 36.7 %. Patients with a positive cannulated test had a higher prolactin at T0, which was 888.5 mME/L (U = 97.0; z = 7.92; p < 0.001). Patients with stress-induced HP (negative test) and patients with true HP (positive test) had no statistically significant differences in age and occurrence frequency of specific and non-specific complaints and symptoms for HP.","PeriodicalId":20584,"journal":{"name":"Proceedings of the National Academy of Sciences of Belarus, Medical series","volume":"91 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140265694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-04DOI: 10.29235/1814-6023-2024-21-1-7-15
F. Vismont
It is known that the severity of endotoxemia and the body temperature level largely depends on the liver functional state and its detoxication function. It was shown that the adrenoreactive systems of the hypothalamus under the influence of extreme irritants on the body have a pronounced effect on all vital processes and, in particular, on thermoregulation and detoxication.The objective of the study was to determine the significance of central adrenoreactive systems in the regulation of the liver detoxication function and body temperature during bacterial endotoxemia. Research methods are: physiological, biochemical, pharmacological.Experiments on rats and rabbits showed that the direction and nature of body temperature changes under the action of E. coli bacterial endotoxin depend on the severity of endotoxemia and the state of the liver detoxication function. It was revealed that when bacterial endotoxin is introduced into the body in trace concentrations, it increases, and with severe endotoxinemia, the body temperature and the activity of detoxication processes decrease. It was established that the ambiguous direction and nature of body temperature and detoxication changes under the conditions of endotoxemia depend on its severity. It was revealed that depending on the liver functional state, its detoxication function (oneor three-fold inoculation of animals with carbon tetrachloride), the same dose of bacterial endotoxin can lead to increasing the rat body temperature, has no effect on it, or can cause hypothermia. It was established that the activity of αand β-adrenoreactive systems of the hypothalamic region of the brain is important in the regulation of detoxication processes and body temperature during bacterial endotoxemia. A decrease in the activity of α-adrenergic receptors in the brain under the influence of bacterial endotoxin appears to be one of the triggers in the chain of processes leading to a body temperature increase and detoxication.
{"title":"Participation of central adrenoreactive systems in the regulation of the liver detoxication function and body temperature in bacterial endotoxinemia","authors":"F. Vismont","doi":"10.29235/1814-6023-2024-21-1-7-15","DOIUrl":"https://doi.org/10.29235/1814-6023-2024-21-1-7-15","url":null,"abstract":"It is known that the severity of endotoxemia and the body temperature level largely depends on the liver functional state and its detoxication function. It was shown that the adrenoreactive systems of the hypothalamus under the influence of extreme irritants on the body have a pronounced effect on all vital processes and, in particular, on thermoregulation and detoxication.The objective of the study was to determine the significance of central adrenoreactive systems in the regulation of the liver detoxication function and body temperature during bacterial endotoxemia. Research methods are: physiological, biochemical, pharmacological.Experiments on rats and rabbits showed that the direction and nature of body temperature changes under the action of E. coli bacterial endotoxin depend on the severity of endotoxemia and the state of the liver detoxication function. It was revealed that when bacterial endotoxin is introduced into the body in trace concentrations, it increases, and with severe endotoxinemia, the body temperature and the activity of detoxication processes decrease. It was established that the ambiguous direction and nature of body temperature and detoxication changes under the conditions of endotoxemia depend on its severity. It was revealed that depending on the liver functional state, its detoxication function (oneor three-fold inoculation of animals with carbon tetrachloride), the same dose of bacterial endotoxin can lead to increasing the rat body temperature, has no effect on it, or can cause hypothermia. It was established that the activity of αand β-adrenoreactive systems of the hypothalamic region of the brain is important in the regulation of detoxication processes and body temperature during bacterial endotoxemia. A decrease in the activity of α-adrenergic receptors in the brain under the influence of bacterial endotoxin appears to be one of the triggers in the chain of processes leading to a body temperature increase and detoxication.","PeriodicalId":20584,"journal":{"name":"Proceedings of the National Academy of Sciences of Belarus, Medical series","volume":"93 19","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140079854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-04DOI: 10.29235/1814-6023-2024-21-1-68-78
V. A. Chуzhуk, М. М. Sialitski, V. V. Ponomarev
Parkinson’s disease (PD) is a chronic progressive disease. Currently, PD treatment is symptomatic. One of the promising directions changing the PD therapy course is the use of autologous multipotent mesenchymal stromal cells (MMSCs). Despite the encouraging results in various preclinical and clinical trials and proven safety, the cell therapy questions remain open, such as the choice of an optimal route of administration, dose, and frequency of treatment courses.In the present study, the dynamics of PD motor and non-motor symptoms was assessed after the first and second cell therapy courses using MMSC injections via systemic and tandem methods during a long-term period. A positive therapy effect on the dynamics of motor and non-motor symptoms in patients with PD was revealed for an average of 6 months after one MMSC treatment course. The repeated MMSC treatment course has similar efficacy and safety to the first course and can be used to slow down the PD progression for a longer period.
{"title":"Efficacy and safety of primary and repeated therapy courses of Parkinson’s disease with autologous mesenchymal stromal cells in the long-term period","authors":"V. A. Chуzhуk, М. М. Sialitski, V. V. Ponomarev","doi":"10.29235/1814-6023-2024-21-1-68-78","DOIUrl":"https://doi.org/10.29235/1814-6023-2024-21-1-68-78","url":null,"abstract":"Parkinson’s disease (PD) is a chronic progressive disease. Currently, PD treatment is symptomatic. One of the promising directions changing the PD therapy course is the use of autologous multipotent mesenchymal stromal cells (MMSCs). Despite the encouraging results in various preclinical and clinical trials and proven safety, the cell therapy questions remain open, such as the choice of an optimal route of administration, dose, and frequency of treatment courses.In the present study, the dynamics of PD motor and non-motor symptoms was assessed after the first and second cell therapy courses using MMSC injections via systemic and tandem methods during a long-term period. A positive therapy effect on the dynamics of motor and non-motor symptoms in patients with PD was revealed for an average of 6 months after one MMSC treatment course. The repeated MMSC treatment course has similar efficacy and safety to the first course and can be used to slow down the PD progression for a longer period.","PeriodicalId":20584,"journal":{"name":"Proceedings of the National Academy of Sciences of Belarus, Medical series","volume":"57 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140080583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-04DOI: 10.29235/1814-6023-2024-21-1-53-61
A. M. Tsygankov, O. V. Gribovskaya, V. Martinovich, V. Golubovich, N. V. Khairulina, U. V. Yanchanka
Experience with pandemics strongly suggests that vaccination of the population in all categories should be a national priority. The choice of a vaccine production platform should be made in such a way as to achieve an optimal effect at the lowest possible cost. A peptide vaccine or a protein platform vaccine could serve these purposes. Oral and intranasal vaccines are also attractive due to the ease of administration to different population groups, and the resulting immunity is not inferior to that of intramuscularly administered vaccines.In this work, synthetic peptides representing the fragments of the surface protein SARS-CoV-2 were investigated. The peptides were prepared by classical peptide synthesis, with peptide No. 1 (Lys-Ile-Ala-Asp-Tyr-Asn-Tyr-Lys-Leu) being immunodominant for the HLA-A02:01 phenotype with a low calculated concentration of half-maximum inhibition. Peptide No. 2 (Val-Arg-Gln-Ala-Pro-Asn-Gly-Gln-Thr) was chosen as control and is not immunodominant for the HLA-A02:01 phenotype, with a high estimated concentration of half-maximum inhibition (IC50).80 persons were questionnaired and 78 volunteers were examined. Cellular immunity parameters were analyzed using a Cytomics FC 500 flow cytometer and gamma interferon (IFN-γ) was determined by ELISA. The results were processed using Statistica 10 software. As a result, a new method was tested to evaluate the activation of blood leukocytes by synthetic peptides. Regardless of the HLA-A phenotype of the study subjects, the peptides were able to bind to leukocytes, indicating a universal response to foreign peptides, especially to innate immune cells. Peptide No. 2 with high calculated IC50, compared to peptide No. 1 with low calculated IC50, showed significantly higher binding to lymphocytes and monocytes and activation of basophils. The peptides used in this work showed that they interact with leukocytes, activating them through the secretion of IFN-γ. Thus, our work demonstrates an approach to creating a peptide vaccine in the in vitro research phase, as well as to studying the antiviral response by the IFN-γ growth in response to the peptides.
{"title":"Activating the leukocytes by short synthetic peptides in vitro as a stage in the creation of treatment-prophylactic vaccines against COVID-19","authors":"A. M. Tsygankov, O. V. Gribovskaya, V. Martinovich, V. Golubovich, N. V. Khairulina, U. V. Yanchanka","doi":"10.29235/1814-6023-2024-21-1-53-61","DOIUrl":"https://doi.org/10.29235/1814-6023-2024-21-1-53-61","url":null,"abstract":"Experience with pandemics strongly suggests that vaccination of the population in all categories should be a national priority. The choice of a vaccine production platform should be made in such a way as to achieve an optimal effect at the lowest possible cost. A peptide vaccine or a protein platform vaccine could serve these purposes. Oral and intranasal vaccines are also attractive due to the ease of administration to different population groups, and the resulting immunity is not inferior to that of intramuscularly administered vaccines.In this work, synthetic peptides representing the fragments of the surface protein SARS-CoV-2 were investigated. The peptides were prepared by classical peptide synthesis, with peptide No. 1 (Lys-Ile-Ala-Asp-Tyr-Asn-Tyr-Lys-Leu) being immunodominant for the HLA-A02:01 phenotype with a low calculated concentration of half-maximum inhibition. Peptide No. 2 (Val-Arg-Gln-Ala-Pro-Asn-Gly-Gln-Thr) was chosen as control and is not immunodominant for the HLA-A02:01 phenotype, with a high estimated concentration of half-maximum inhibition (IC50).80 persons were questionnaired and 78 volunteers were examined. Cellular immunity parameters were analyzed using a Cytomics FC 500 flow cytometer and gamma interferon (IFN-γ) was determined by ELISA. The results were processed using Statistica 10 software. As a result, a new method was tested to evaluate the activation of blood leukocytes by synthetic peptides. Regardless of the HLA-A phenotype of the study subjects, the peptides were able to bind to leukocytes, indicating a universal response to foreign peptides, especially to innate immune cells. Peptide No. 2 with high calculated IC50, compared to peptide No. 1 with low calculated IC50, showed significantly higher binding to lymphocytes and monocytes and activation of basophils. The peptides used in this work showed that they interact with leukocytes, activating them through the secretion of IFN-γ. Thus, our work demonstrates an approach to creating a peptide vaccine in the in vitro research phase, as well as to studying the antiviral response by the IFN-γ growth in response to the peptides.","PeriodicalId":20584,"journal":{"name":"Proceedings of the National Academy of Sciences of Belarus, Medical series","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140266336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-04DOI: 10.29235/1814-6023-2024-21-1-62-67
A. Putyatina, L. B. Kim, G. S. Russkikh
The paper presents the study results of the organs of mice without (control group) and with BCG-induced granulomatosis. The contents of hydroxyproline (Hyp) fractions (free, peptide-bound, and protein-bound) were measured in the liver, lungs, and spleen by our alkaline hydrolysis method. In mice with BCG-induced granulomatosis, an increased content of Hyp fractions, reflecting the collagen synthesis, was observed, while the content of free Hyp, characterizing the collagen degradation, did not differ from similar indicators of the control group. The analysis of the ratios of individual Hyp fractions showed a different fibrosis degree in the organs. It was high in the lungs, moderate in the liver and weak in the spleen, thus indicating the organ-specific fibrogenesis in tuberculous infection.
{"title":"Assessing the collagen metabolism in experimental BCG-induced tuberculous inflammation","authors":"A. Putyatina, L. B. Kim, G. S. Russkikh","doi":"10.29235/1814-6023-2024-21-1-62-67","DOIUrl":"https://doi.org/10.29235/1814-6023-2024-21-1-62-67","url":null,"abstract":"The paper presents the study results of the organs of mice without (control group) and with BCG-induced granulomatosis. The contents of hydroxyproline (Hyp) fractions (free, peptide-bound, and protein-bound) were measured in the liver, lungs, and spleen by our alkaline hydrolysis method. In mice with BCG-induced granulomatosis, an increased content of Hyp fractions, reflecting the collagen synthesis, was observed, while the content of free Hyp, characterizing the collagen degradation, did not differ from similar indicators of the control group. The analysis of the ratios of individual Hyp fractions showed a different fibrosis degree in the organs. It was high in the lungs, moderate in the liver and weak in the spleen, thus indicating the organ-specific fibrogenesis in tuberculous infection.","PeriodicalId":20584,"journal":{"name":"Proceedings of the National Academy of Sciences of Belarus, Medical series","volume":"37 10","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140080641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-04DOI: 10.29235/1814-6023-2024-21-1-26-32
S. Rubnikovich, L. N. Dedova, Yulia L. Denisova, A. S. Solomevich
The main predisposing factors for DS occurrence and development in dental patients have been identified, and the DS prognosis program and the DS prognosis index have been developed.The program and the prognosis index were tested in 95 dental patients. The control group consisted of 30 patients. Clinical parameters were assessed before treatment, after 1 week, and 1, 6, 12 months. The treatment effectiveness was assessed using the number of good, satisfactory, and unsatisfactory treatment results in each group.The results of clinical observation of patients showed that the use of the DS prognosis program and the DS prognosis index makes it possible not only to clearly inform patients about the level of risk of developing DS, but also to constantly monitor prognostic signs, which increases the treatment effectiveness by 47 %.Good treatment results in 97 % of cases in a long-term period determine the feasibility of including the program we developed and the prognosis index in the complex treatment of DS in dental patients.
{"title":"Predicting the risk of dentin sensitivity development in dental patients","authors":"S. Rubnikovich, L. N. Dedova, Yulia L. Denisova, A. S. Solomevich","doi":"10.29235/1814-6023-2024-21-1-26-32","DOIUrl":"https://doi.org/10.29235/1814-6023-2024-21-1-26-32","url":null,"abstract":"The main predisposing factors for DS occurrence and development in dental patients have been identified, and the DS prognosis program and the DS prognosis index have been developed.The program and the prognosis index were tested in 95 dental patients. The control group consisted of 30 patients. Clinical parameters were assessed before treatment, after 1 week, and 1, 6, 12 months. The treatment effectiveness was assessed using the number of good, satisfactory, and unsatisfactory treatment results in each group.The results of clinical observation of patients showed that the use of the DS prognosis program and the DS prognosis index makes it possible not only to clearly inform patients about the level of risk of developing DS, but also to constantly monitor prognostic signs, which increases the treatment effectiveness by 47 %.Good treatment results in 97 % of cases in a long-term period determine the feasibility of including the program we developed and the prognosis index in the complex treatment of DS in dental patients.","PeriodicalId":20584,"journal":{"name":"Proceedings of the National Academy of Sciences of Belarus, Medical series","volume":"23 S1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140265834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-04DOI: 10.29235/1814-6023-2024-21-1-33-42
T. Barysenka, V. A. Snezhitskiy, M. N. Kurbat, O. V. Gorchakova, A. Kopytsky
Asymptomatic hyperuricemia (HU) is widespread in the population and is one of the main risk factors for cardiovascular diseases. Evidence of numerous studies supports the association between increased uric acid (UA) levels and the risk of arterial hypertension (HTN) and/or atrial fibrillation (AF). One of the causes for an increase in UA levels and a significant risk factor for HU is the polymorphism of the SLC2A9 gene, a highly specific urate transporter in proximal renal tubule cells, encoding the GLUT9 protein.The aim of the study is to investigate the frequency of genotypes and alleles of the SLC2A9 gene rs734553 polymorphic variant and its association with the UA level in patients with HTN and AF, as well as in healthy individuals. 141 patients, including 50 healthy patients (group 1), 68 – with HTN and AF (group 2), 23 – with HTN (group 3) were examined.In the overall group of patients, the frequencies of the SLC2A9 gene rs734553 polymorphism were as follows: AA – 46.1 % (n = 65), AC – 36.2 % (n = 51), CC – 17.7 % (n = 25). According to the genotyping results of patients, in group 1 the AA genotype was 64 % (n = 32), AC – 22 % (n = 11), CC – 14 % (n = 7); in group 2 – 32.4 % (n = 22), 48.5 % (n = 33) and 19.1 % (n = 13); in group 3 47.8 % (n = 11), 30.4 % (n = 7) and 21.7 % (n = 5), respectively. The CC genotype patients (420 [413; 424] μmol/l) and the AC genotype patients (330 [284; 412] μmol/l) had higher uricemia values than those with the AA genotype (310 [281; 341] μmol/l) ( p = 0,003). HU with the AA genotype in group 2 was diagnosed in 2 (2.9 %) patients, with the AC genotype in 12 (17.6 %), and with the CC genotype in 10 (14.7 %) patients; in group 3 – 1 (4.3 %), 1 (4.3 %) and 3 (13 %), respectively. One patient (2 %) with HU in group 1 had the CC genotype.The distribution of genotype and allele frequencies of the SLC2A9 gene rs734553 polymorphic variant and its association with the UA level in patients with HTN and AF, as well as in healthy individuals were established. In patients with HTN and AF, the AC genotype occurred 3 times more often and the CC genotype occurred 2 times more often than in healthy patients. HU occurred significantly more often ( р = 0.003) in the group of patients with HTN and AF and the CC genotype, as well as in patients with the CC genotype.
{"title":"Distribution of the SLC2A9 genotype and its association with the uric acid level in patients with arterial hypertension and atrial fibrillation","authors":"T. Barysenka, V. A. Snezhitskiy, M. N. Kurbat, O. V. Gorchakova, A. Kopytsky","doi":"10.29235/1814-6023-2024-21-1-33-42","DOIUrl":"https://doi.org/10.29235/1814-6023-2024-21-1-33-42","url":null,"abstract":"Asymptomatic hyperuricemia (HU) is widespread in the population and is one of the main risk factors for cardiovascular diseases. Evidence of numerous studies supports the association between increased uric acid (UA) levels and the risk of arterial hypertension (HTN) and/or atrial fibrillation (AF). One of the causes for an increase in UA levels and a significant risk factor for HU is the polymorphism of the SLC2A9 gene, a highly specific urate transporter in proximal renal tubule cells, encoding the GLUT9 protein.The aim of the study is to investigate the frequency of genotypes and alleles of the SLC2A9 gene rs734553 polymorphic variant and its association with the UA level in patients with HTN and AF, as well as in healthy individuals. 141 patients, including 50 healthy patients (group 1), 68 – with HTN and AF (group 2), 23 – with HTN (group 3) were examined.In the overall group of patients, the frequencies of the SLC2A9 gene rs734553 polymorphism were as follows: AA – 46.1 % (n = 65), AC – 36.2 % (n = 51), CC – 17.7 % (n = 25). According to the genotyping results of patients, in group 1 the AA genotype was 64 % (n = 32), AC – 22 % (n = 11), CC – 14 % (n = 7); in group 2 – 32.4 % (n = 22), 48.5 % (n = 33) and 19.1 % (n = 13); in group 3 47.8 % (n = 11), 30.4 % (n = 7) and 21.7 % (n = 5), respectively. The CC genotype patients (420 [413; 424] μmol/l) and the AC genotype patients (330 [284; 412] μmol/l) had higher uricemia values than those with the AA genotype (310 [281; 341] μmol/l) ( p = 0,003). HU with the AA genotype in group 2 was diagnosed in 2 (2.9 %) patients, with the AC genotype in 12 (17.6 %), and with the CC genotype in 10 (14.7 %) patients; in group 3 – 1 (4.3 %), 1 (4.3 %) and 3 (13 %), respectively. One patient (2 %) with HU in group 1 had the CC genotype.The distribution of genotype and allele frequencies of the SLC2A9 gene rs734553 polymorphic variant and its association with the UA level in patients with HTN and AF, as well as in healthy individuals were established. In patients with HTN and AF, the AC genotype occurred 3 times more often and the CC genotype occurred 2 times more often than in healthy patients. HU occurred significantly more often ( р = 0.003) in the group of patients with HTN and AF and the CC genotype, as well as in patients with the CC genotype.","PeriodicalId":20584,"journal":{"name":"Proceedings of the National Academy of Sciences of Belarus, Medical series","volume":"5 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140266523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-04DOI: 10.29235/1814-6023-2024-21-1-43-52
V. М. Sheybak, A. Y. Pavlyukovets, E. M. Doroshenko
One of the main hydrophobic amino acids – tryptophan and essential trace element zinc perform numerous and largely overlapping functions in the mammalian body. A huge number of zinc-containing compounds – proteins, enzymes, transcription factors, and hormones interact with tryptophan metabolites. We have attempted to identify the main effects of amino acids and trace elements on amino acid metabolism in order to determine the general mechanisms and the feasibility of their possible therapeutic use.We have found that the course administration of tryptophan at a dose of 40 mg/kg in blood plasma reduces the total amount of ARUC and increases the concentration of free tryptophan. In animals treated with zinc diaspartate or zinc diaspartate together with tryptophan, the total amount of amino acids and their nitrogen-containing metabolites in blood plasma de creases. The analysis of individual concentrations of amino acids and their nitrogen-containing metabolites showed that the coadministration of tryptophan and zinc diaspartate is accompanied by statistically significant changes in the concentrations of most of the studied parameters of the amino acid pool (19 out of 35 parameters). It should be noted that the changes in the content of free amino acids and their nitrogen-containing metabolites are unidirectional in the groups of animals treated with zinc diaspartate or zinc diaspartate together with tryptophan (coincidence of effects is 90 %). Thus, our studies showed that the course administration of zinc diaspartate at a dose of 25 mg/kg (2 times higher than an average therapeutic dose) has a pronounced metabolic effect, characterized by changes in the concentrations of free amino acids and their nitrogen-containing metabolites in blood plasma. The course administration of tryptophan at a dose of 40 mg/ kg of body weight (1/2 of a therapeutic dose) has no significant effect on the parameters of the blood plasma aminogram. With the coadministration of zinc diaspartate and tryptophan in the above doses, the revealed changes can be more attributed to the effects of zinc diaspartate.
{"title":"Tryptophan and zinc: effect of co-administration on plasma free amino acid homeostasis","authors":"V. М. Sheybak, A. Y. Pavlyukovets, E. M. Doroshenko","doi":"10.29235/1814-6023-2024-21-1-43-52","DOIUrl":"https://doi.org/10.29235/1814-6023-2024-21-1-43-52","url":null,"abstract":"One of the main hydrophobic amino acids – tryptophan and essential trace element zinc perform numerous and largely overlapping functions in the mammalian body. A huge number of zinc-containing compounds – proteins, enzymes, transcription factors, and hormones interact with tryptophan metabolites. We have attempted to identify the main effects of amino acids and trace elements on amino acid metabolism in order to determine the general mechanisms and the feasibility of their possible therapeutic use.We have found that the course administration of tryptophan at a dose of 40 mg/kg in blood plasma reduces the total amount of ARUC and increases the concentration of free tryptophan. In animals treated with zinc diaspartate or zinc diaspartate together with tryptophan, the total amount of amino acids and their nitrogen-containing metabolites in blood plasma de creases. The analysis of individual concentrations of amino acids and their nitrogen-containing metabolites showed that the coadministration of tryptophan and zinc diaspartate is accompanied by statistically significant changes in the concentrations of most of the studied parameters of the amino acid pool (19 out of 35 parameters). It should be noted that the changes in the content of free amino acids and their nitrogen-containing metabolites are unidirectional in the groups of animals treated with zinc diaspartate or zinc diaspartate together with tryptophan (coincidence of effects is 90 %). Thus, our studies showed that the course administration of zinc diaspartate at a dose of 25 mg/kg (2 times higher than an average therapeutic dose) has a pronounced metabolic effect, characterized by changes in the concentrations of free amino acids and their nitrogen-containing metabolites in blood plasma. The course administration of tryptophan at a dose of 40 mg/ kg of body weight (1/2 of a therapeutic dose) has no significant effect on the parameters of the blood plasma aminogram. With the coadministration of zinc diaspartate and tryptophan in the above doses, the revealed changes can be more attributed to the effects of zinc diaspartate.","PeriodicalId":20584,"journal":{"name":"Proceedings of the National Academy of Sciences of Belarus, Medical series","volume":"82 21","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140080158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-04DOI: 10.29235/1814-6023-2024-21-1-16-25
A. S. Doronkina, A. A. Rudak, I. P. Zhavoronok, V. G. Bogdan
3D modeling of fatty acid amides was carried out in order to study their bioavailability indicators. Fatty acid amide complexes with the PPARα receptor were constructed by molecular docking. It was shown that fatty acid amides, based on Lipinsky’s rule of five, due to their low solubility in water, high lipophilicity and flexibility, have weak bioavailability, which limits their digestibility when taken orally. As a result of docking fatty acid amides with the PPARα receptor, stable complexes are formed. They are characterized by the presence of hydrogen bonds and a network of Van der Waals contacts.
{"title":"Virtual screening of the biological activity of fatty acid amides","authors":"A. S. Doronkina, A. A. Rudak, I. P. Zhavoronok, V. G. Bogdan","doi":"10.29235/1814-6023-2024-21-1-16-25","DOIUrl":"https://doi.org/10.29235/1814-6023-2024-21-1-16-25","url":null,"abstract":"3D modeling of fatty acid amides was carried out in order to study their bioavailability indicators. Fatty acid amide complexes with the PPARα receptor were constructed by molecular docking. It was shown that fatty acid amides, based on Lipinsky’s rule of five, due to their low solubility in water, high lipophilicity and flexibility, have weak bioavailability, which limits their digestibility when taken orally. As a result of docking fatty acid amides with the PPARα receptor, stable complexes are formed. They are characterized by the presence of hydrogen bonds and a network of Van der Waals contacts.","PeriodicalId":20584,"journal":{"name":"Proceedings of the National Academy of Sciences of Belarus, Medical series","volume":"150 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140265497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-12-02DOI: 10.29235/1814-6023-2023-20-4-308-315
D. V. Bukach, O. Eismont, M. P. Potapnev, V. I. Asaevich, P. V. Litskevich, F. N. Karpenko, S. I. Krivenko, V. G. Bogdan, V. V. Vusau, K. E. Hahelko
Among the conservative methods of treatment of osteoarthritis the use of plasma enriched with soluble platelet factors /platelet-rich plasma (PORFT/PRP) is becoming increasingly attractive.The aim of the study was to determine the tolerability and effect of intra-articular administration of standardized autologous PRP on patients with knee osteoarthritis status based on the survey results. Patients with knee osteoarthritis (OA) received standard drug therapy (n = 19) or additionally standardized autologous platelet-rich plasma (PRP) (n = 21). Intraarticular injection of 6 ml of PRP was carried out three times every two weeks. The administration safety was assessed. Patients were questioned with an assessment of VAS and WOMAC scales in 2 weeks, 1 month and 3 months after starting the treatment. It was shown that three-time intra-articular administration of standardized autologous PRP was safe for a patient. At the same time, the pain syndrome decreased (VAS score) and the knee joint function improved (WOMAC score) after 1 and 3 months. All indicators were significantly better compared to the control group. We concluded that standardized autologous PORFT with three intra-articular injections is safe and has an analgesic effect and preserves the function of the knee joint already within 1–3 months of observation.
{"title":"Use of autologous platelet-rich plasma in knee osteoarthritis symptomatic treatment","authors":"D. V. Bukach, O. Eismont, M. P. Potapnev, V. I. Asaevich, P. V. Litskevich, F. N. Karpenko, S. I. Krivenko, V. G. Bogdan, V. V. Vusau, K. E. Hahelko","doi":"10.29235/1814-6023-2023-20-4-308-315","DOIUrl":"https://doi.org/10.29235/1814-6023-2023-20-4-308-315","url":null,"abstract":"Among the conservative methods of treatment of osteoarthritis the use of plasma enriched with soluble platelet factors /platelet-rich plasma (PORFT/PRP) is becoming increasingly attractive.The aim of the study was to determine the tolerability and effect of intra-articular administration of standardized autologous PRP on patients with knee osteoarthritis status based on the survey results. Patients with knee osteoarthritis (OA) received standard drug therapy (n = 19) or additionally standardized autologous platelet-rich plasma (PRP) (n = 21). Intraarticular injection of 6 ml of PRP was carried out three times every two weeks. The administration safety was assessed. Patients were questioned with an assessment of VAS and WOMAC scales in 2 weeks, 1 month and 3 months after starting the treatment. It was shown that three-time intra-articular administration of standardized autologous PRP was safe for a patient. At the same time, the pain syndrome decreased (VAS score) and the knee joint function improved (WOMAC score) after 1 and 3 months. All indicators were significantly better compared to the control group. We concluded that standardized autologous PORFT with three intra-articular injections is safe and has an analgesic effect and preserves the function of the knee joint already within 1–3 months of observation.","PeriodicalId":20584,"journal":{"name":"Proceedings of the National Academy of Sciences of Belarus, Medical series","volume":"23 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138606943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：